- Home
- CSQ vs SUPN Comparison
CSQ vs SUPN Comparison
Compare CSQ & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CSQ | SUPN |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.8B |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | CSQ | SUPN |
|---|---|---|
| Price | $18.55 | $49.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $61.60 |
| AVG Volume (30 Days) | 343.0K | ★ 490.1K |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 7.53% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $392,755,000.00 |
| Revenue This Year | N/A | $22.72 |
| Revenue Next Year | N/A | $18.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.45 | $29.16 |
| 52 Week High | $19.83 | $59.68 |
Technical Indicators
Market Signals| Indicator | CSQ | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 61.52 | 44.69 |
| Support Level | $18.04 | $49.46 |
| Resistance Level | $19.52 | $52.25 |
| Average True Range (ATR) | 0.38 | 1.53 |
| MACD | 0.21 | 0.06 |
| Stochastic Oscillator | 96.64 | 34.68 |
Price Performance
Historical ComparisonAbout CSQ Calamos Strategic Total Return
Calamos Strategic Total Return Fund is a diversified, closed-end management investment company. The fund's objective is to provide total return through a combination of capital appreciation and current income. Its investment portfolio comprises equities, convertible securities, and high-yield corporate bonds.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.